ClinicalTrials.gg
RecruitingNCT07169552Updated Dec 17, 2025

HC010 in First-line PD-L1 Positive Advanced NSCLC Patients

A Phase 2 interventional study of HC010 in NSCLC, sponsored by HC Biopharma Inc.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by HC Biopharma Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Phase 2 clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity profile of HC010 for injection in patients with positive PD-L1 (TPS ≥1%)

Read the detailed description

This is a multicenter, single-arm, open-label Phase 2 clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity profile of HC010 for injection as monotherapy in first-line treatment of locally advanced or metastatic non-small cell lung cancer with positive PD-L1 (TPS ≥1%), negative EGFR mutations and negative ALK.

02

Conditions studied

  • NSCLC
03

In context

Lead sponsor

HC Biopharma Inc. is the lead sponsor of 9 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Voluntarily participate in the study, communicate well with investigators, understand and voluntarily complete the study process according to this protocol, and sign the form (ICF).
  • 2. Male or female, aged ≥ 18 years at the time of signing the informed consent form.
  • 3. or cytologically confirmed locally advanced or (stage IIIb\~IV) NSCLC (United States Cancer Confederation [AJCC] 8th edition), positive expression confirmed by IHC with central laboratory or local test results.
  • 4. Not previously receiving systemic therapy for locally advanced or metastatic NSCLC; not allowed if the last dose of prior treatment is \<6 months from disease recurrence in subjects who received prior or neoadjuvant therapy.
  • 5. No EGFR mutation/ROS1 rearrangement/ALK rearrangement. If other targeted mutations such as BRAF V600E mutation/NTRK1/2/3 gene fusion/MET14 exon skipping mutation/RET rearrangement positive are known, they will not be included in this study if the corresponding targeted therapy drugs have been approved.
  • 6. Expected survival ≥ 3 months.
  • 7.There should be at least one according to v1.1; radiotherapy-experienced lesions may not be selected as target lesions, unless the radiotherapy lesion is the only measurable lesion and clearly progresses based on imaging judgment.
  • 8. (ECOG) performance status scored 0 or 1 in the United States and did not worsen within one week prior to first dose.
  • 9. Subjects (both female and male) agreed to use effective from signing the ICF until 180 days after last dose of product. Female patients of must have a negative blood or urine pregnancy test within 7 days prior to the first dose; females who are not pregnant or lactating from signing informed consent until 6 months after the last use of investigational drug (including those who agree to stop breastfeeding during this period).

Exclusion criteria

Exclusion Criteria:

  • 1. Subjects who have received Chinese patent medicine or immunomodulatory drugs (including but not limited to thymopeptide, interferon and interleukin) with anti-tumor indications within 2 weeks before the first dose;
  • 2. Pulmonary radiation therapy >30 Gy within 6 months prior to the first dose;
  • 3. Complete palliative radiotherapy within 7 days before the first dose;
  • 4. Any other form of anti-tumor therapy is expected to be required during the study;
  • 5. Pericardial effusion (a stable small amount of pericardium can be included actively), or uncontrolled or symptomatic pleural and ascites effusions requiring puncture drainage;
  • 6. Presence of brain stem, meningeal /meningitis carcinoma, spinal cord metastasis or compression;
  • 7. Known . Previously treated subjects with brain metastasis may participate in the study if they are clinically stable for at least 4 weeks prior to first dose, have no evidence of new or expanded brain metastases, and discontinue 7 days prior to first dose. According to this definition, the stability of brain metastasis should be established prior to the first dose of study drug. Subjects with known untreated asymptomatic brain metastases stable for at least 4 weeks (i.e., no neurological symptoms, no corticosteroid treatment required, no or only slight peripheral edema, no lesion >1.5 cm, or stable brain lesion as determined by imaging) can participate in the study;
  • 8. Patients who have taken systemic corticosteroids (> 10 mg prednisone or equivalent daily) or other drugs (such as cyclophosphamide, azathioprine, methotrexate, thalidomide, TNF-α inhibitors, etc.) within 2 weeks prior to the first dose;
  • 9. Systemic infection or other serious infection requiring intravenous antibiotics for >7 days within 2 weeks prior to the first dose, or fever of unexplained origin >38.5 °C during screening and before enrollment (except for fever due to tumor in the investigator's judgment).
  • 10. Concurrent with other malignant tumors within 5 years before the first dose, except for patients with adequately treated cervical carcinoma in situ, basal cell, squamous epithelial cell skin cancer, papillary thyroid carcinoma, local prostate cancer after radical resection and ductal carcinoma in situ after radical resection;
  • 11. Subjects with diseases that may jeopardize their safety or compliance with the study protocol, and other conditions unsuitable for participation in this study as judged by the investigator.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    HC010

    Drug: HC010

Interventions

  • DrugHC010

    HC010 Q3W intravenous infusion

06

What researchers measure

Primary outcomes

  1. ORR

    Objective response rate (ORR) assessed by the investigator according to RECIST 1.1 criteria;

    Time frame: 24months

Secondary outcomes

  1. Safety and tolerability

    Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), and clinically significant abnormal laboratory results.

    Time frame: 24 months

  2. DCR

    Disease control rate (DCR), which is defined as the proportion of subjects with CR, PR, or SD, based on RECIST v1.1

    Time frame: 24 months

  3. DoR

    Duration of response (DoR), which is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first.

    Time frame: 24 months

  4. PFS

    PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first assessed by investigator Per RECIST 1.1.

    Time frame: 24 months

  5. OS

    Overall Survival (OS) in the ITT population

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Dec 2026, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2025
First posted
Sep 11, 2025
StartEst.
Dec 9, 2025
Primary completionEst.
Dec 30, 2026
CompletionEst.
Sep 30, 2027
Last update
Dec 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07169552
Lead sponsor
HC Biopharma Inc.
Responsible party
Sponsor
First posted
Sep 11, 2025
Start date
Dec 9, 2025 (estimated)
Primary completion
Dec 30, 2026 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Dec 17, 2025

Study contacts

QiQi Huang, master
Contact
qiqi.huang@btyy.com
18221247718

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion